Molecular Recognition of Basic Fibroblast Growth Factor by Polyoxometalates

Controlled drug delivery and cell adhesion for bone tissue regeneration by Keplerate polyoxometalate (Mo132)/metronidazole/PMMA scaffolds

The aim of this study is to fabricate a new scaffold appropriate for tissue regeneration with antimicrobial activity and ability of controlled drug delivery. In this regard, scaffold nanofibers were produced using poly (methyl methacrylate) (PMMA), Mo₁₃₂ as a Keplerate polyoxometalate and metronidazole. The final scaffolds, obtained by electrospinning, represent the intrinsic features including exceptional doubling tensile strength, high hydrophilicity (126 ± 5.2° to 83.9 ± 3.2° for contact angle and 14.18 ± 0.62% to 35.62 ± 0.24% for water uptake), proper bioactivity and cell adhesion. Moreover, the addition of Mo₁₃₂ and metronidazole enhances the biodegradation rate of resulted scaffolds compared to the pure PMMA membrane. The controlled release of metronidazole over 14 days efficiently inhibits the colonization of anaerobic microorganisms. Overall, the results demonstrate high potential of Mo₁₃₂ and metronidazole-loaded PMMA scaffold for guided bone regeneration/guided tissue regeneration.

Site-Directed Chemical Modification of Amyloid by Polyoxometalates for Inhibition of Protein Misfolding and Aggregation

Post-translational modification (PTM) of protein can significantly change protein conformation and function. Inspired by the natural PTM, we present a new approach to inhibit amyloid aggregation by chemical PTM modification. Polyoxometalates (POMs) were used as examples of inhibitors of β-amyloid peptide (Aβ) aggregation to illustrate the chemical PTM method. After the POMs were modified with thiazolidinethione (TZ), the resulting POMD-TZ acted as a chemical PTM agent and could covalently modify Aβ site-selectively at Lys16. Multiple biophysical techniques and biochemical assays have been employed to show the superiority of the chemical PTM method compared to traditional Aβ inhibitors. Since Aβ oligomers are more cytotoxic, we further functionalized POMD-TZ with an Aβ-targeted peptide and a fluorescent probe to obtain an "Aβ oligomer sensitive" probe. The use of PTM agents for the site-directed chemical modification of proteins provides a new way to regulate amyloid aggregation.

Selenium nanoparticles with various morphology for antiangiogenesis through bFGF-mediated P13K/AKT signaling pathways

Selenium nanoparticles (Se NPs) have potential antitumor activity and immune properties. However, the mechanism between its antitumor activity and nanoparticle morphology has not been evaluated. Therefore, a simple method was used to synthesize three special shapes of Se NPs, which are fusiform, flower and spherical. Compared with fusiform selenium nanoparticles (Se NPs (S)) and flower-shaped selenium nanoparticles (Se NPs (F)), spherical selenium nanoparticles (Se NPs (B)) have better cell absorption effect and stronger antitumor activity. HRTEM showed that Se NPs (B) entered the nucleus through endocytosis and inhibited tumor angiogenesis by targeting basic fibroblast growth factor (bFGF). Se NPs (B) can competitively inhibit the binding of bFGF to fibroblast growth factor receptor through direct binding to bFGF, down-regulate the expression of bFGF in human umbilical vein endothelial cells (HUVEC), and significantly reduce the MAPK/Erk and P13K/AKT pathways activation of signaling molecules to regulate HUVEC cell migration and angiogenesis. These findings indicate that Se NPs have a special role in antitumor angiogenesis. This research provides useful information for the development of new strategies for effective drug delivery nanocarriers and therapeutic systems.

Polyoxometalates as Effective Nano-inhibitors of Amyloid Aggregation of Pro-inflammatory S100A9 Protein Involved in Neurodegenerative Diseases

Pro-inflammatory and amyloidogenic S100A9 protein is central to the amyloid-neuroinflammatory cascade in neurodegenerative diseases. Polyoxometalates (POMs) constitute a diverse group of nanomaterials, which showed potency in amyloid inhibition. Here, we have demonstrated that two selected nanosized niobium POMs, Nb₁₀ and TiNb₉, can act as potent inhibitors of S100A9 amyloid assembly. Kinetics analysis based on ThT fluorescence experiments showed that addition of either Nb₁₀ or TiNb₉ reduces the S100A9 amyloid formation rate and amyloid quantity. Atomic force microscopy imaging demonstrated the complete absence of long S100A9 amyloid fibrils at increasing concentrations of either POM and the presence of only round-shaped and slightly elongated aggregates. Molecular dynamics simulation revealed that both Nb₁₀ and TiNb₉ bind to native S100A9 homo-dimer by forming ionic interactions with the positively charged Lys residue-rich patches on the protein surface. The acrylamide quenching of intrinsic fluorescence showed that POM binding does not perturb the Trp 88 environment. The far and near UV circular dichroism revealed no large-scale perturbation of S100A9 secondary and tertiary structures upon POM binding. These indicate that POM binding involves only local conformational changes in the binding sites. By using intrinsic and 8-anilino-1-naphthalene sulfonate fluorescence titration experiments, we found that POMs bind to S100A9 with a K_d of ca. 2.5 μM. We suggest that the region, including Lys 50 to Lys 54 and characterized by high amyloid propensity, could be the key sequences involved in S1009 amyloid self-assembly. The inhibition and complete hindering of S100A9 amyloid pathways may be used in the therapeutic applications targeting the amyloid-neuroinflammatory cascade in neurodegenerative diseases.

Inhibition of Mitochondrial ATP Synthesis and Regulation of Oxidative Stress Based on {SbW8 O30 } Determined by Single-Cell Proteomics Analysis

The 10-nuclear heteroatom cluster modified {SbW₈ O₃₀ } was successfully synthesized and exhibited inhibitory activity (IC₅₀ =0.29 μM). Based on proteomics analysis, Na₄ Ni₂ Sb₂ W₂ -SbW₈ inhibited ATP production by affecting the expression of 16 related proteins, hindering metabolic functions in vivo and cell proliferation due to reactive oxygen species (ROS) stress. In particular, the low expression of FAD/FMN-binding redox enzymes (relative expression ratio of the experimental group to the control=0.43843) could be attributed to the redox mechanism of Na₄ Ni₂ Sb₂ W₂ -SbW₈ , which was consistent with the effect of polyoxometalates (POMs) and FMN-binding proteins on ATP formation. An electrochemical study showed that Na₄ Ni₂ Sb₂ W₂ -SbW₈ combined with FMN to form Na₄ Ni₂ Sb₂ W₂ -SbW₈ -2FMN complex through a one-electron process of the W atoms. Na₄ Ni₂ Sb₂ W₂ -SbW₈ acted as catalase and glutathione peroxidase to protect the cell from ROS stress, and the inhibition rates were 63.3 % at 1.77 μM of NADPH and 86.06 % at 10.62 μM of 2-hydroxyterephthalic acid. Overall, our results showed that POMs can be specific oxidative/antioxidant regulatory agents.

In Vitro Anti-tumoral and Anti-bacterial Activity of an Octamolybdate Cluster-Based Hybrid Solid Incorporated with a Copper Picolinate Complex

Inorganic drugs, especially polyoxometalate-based hybrids, are expected to be developed as promising future metallodrugs. Herein, an organic-inorganic hybrid solid based on pyridine-2-carboxylic acid or picolinic acid (pic), [(Cu(pic)₂)₂(Mo₈O₂₆)]·8H₂O (1), was synthesized. A single-crystal structure of a solid possesses a discrete β-type octamolybdate cluster that supramolecularly aggregates with a {Cu₂(pic)₄}^4- complex and eight lattice water molecules. The study indicates that the solid is stable in aqueous medium and less toxic toward normal cell lines. The in vitro anti-bacterial and anti-tumor properties of the solid 1 were investigated. The results of the anti-tumor action against various human cancer cell lines, namely, lung (A549), breast (MCF-7), and liver (HepG2) cancer cells suggest that this β-octamolybdate-based solid yielded the lowest IC₅₀ value reported so far among octamolybdate anion-based hybrid solids, i.e., 24.24 μM for MCF-7, 21.56 μM for HepG2, and 25 μM for A549, indicating significant anti-cancer activity. The cell cycle analysis further reveals the observed anti-tumor effect to be governed by the arrest of breast cancer cells in the G2/M phase while that of lung and liver cancer cells in the S phase of the cell cycle. A fluorescence quenching study suggests the binding interaction between solid and ctDNA, which in turn induces apoptosis and necrosis pathways leading to cancer cell death. This is also the first study of {Mo₈O₂₆}^4- cluster-based solids as an anti-bacterial agent against Escherichia coli, and it was found to be very effective with a minimal inhibitory concentration value of ∼135 μg/mL, which is the lowest so far reported for any octamolybdate-based solid.

Manipulating Active Structure and Function of Cationic Antimicrobial Peptide CM15 with the Polysulfonated Drug Suramin: A Step Closer to in Vivo Complexity

Antimicrobial peptides (AMPs) kill bacteria by targeting their membranes through various mechanisms involving peptide assembly, often coupled with disorder-to-order structural transition. However, for several AMPs, similar conformational changes in cases in which small organic compounds of both endogenous and exogenous origin have induced folded peptide conformations have recently been reported. Thus, the function of AMPs and of natural host defence peptides can be significantly affected by the local complex molecular environment in vivo; nonetheless, this area is hardly explored. To address the relevance of such interactions with regard to structure and function, we have tested the effects of the therapeutic drug suramin on the membrane activity and antibacterial efficiency of CM15, a potent hybrid AMP. The results provided insight into a dynamic system in which peptide interaction with lipid bilayers is interfered with by the competitive binding of CM15 to suramin, resulting in an equilibrium dependent on peptide-to-drug ratio and vesicle surface charge. In vitro bacterial tests showed that when CM15⋅suramin complex formation dominates over membrane binding, antimicrobial activity is abolished. On the basis of this case study, it is proposed that small-molecule secondary structure regulators can modify AMP function and that this should be considered and could potentially be exploited in future development of AMP-based antimicrobial agents.

Chirality-Selected Chemical Modulation of Amyloid Aggregation

Due to the composed α-helical/β-strand structures, β-amyloid peptide (Aβ) is sensitive to chiral environments. The orientation and chirality of the Aβ strand strongly influence its aggregation. Aβ-formed fibrils have a cascade of chirality. Therefore, for selectively targeting amyloid aggregates, chirality preference can be one key issue. Inspired by the natural stereoselectivity and the β-sheet structure, herein, we synthesized a series of d- and l-amino acid-modified polyoxometalate (POM) derivatives, including positively charged amino acids (d-His and l-His) and negatively charged (d-Glu and l-Glu) and hydrophobic amino acids (d-Leu, l-Leu, d-Phe, and l-Phe), to modulate Aβ aggregation. Intriguingly, Phe-modified POMs showed a stronger inhibition effect than other amino acid-modified POMs, as evidenced by multiple biophysical and spectral assays, including fluorescence, circular dichroism, NMR, molecular dynamic simulations, and isothermal titration calorimetry. More importantly, d-Phe-modified POM had an 8-fold stronger inhibition effect than l-Phe-modified POM, indicating high enantioselectivity. Furthermore, in vivo studies demonstrated that the chiral POM derivatives crossed the blood-brain barrier, extended the life span of AD transgenic Caenorhabditis elegans CL2006 strain, and had low cytotoxicity, even at a high dosage.

Polyoxomolybdates as α-glucosidase inhibitors: Kinetic and molecular modeling studies

Noninsulin dependent diabetes mellitus is a serious global disease that is treated by inhibiting α-glucosidase to reduce the glucose content in the blood. Several incompletely satisfactory therapeutic drugs are already on the market. In this report, we showed that polyoxomolybdates based on Keggin-type architecture are promising candidates. Kinetic studies indicate that H₃PMo₁₂O₄₀, Na₄PMo₁₁VO₄₀, Na₆PMo₁₁FeO₄₀ and Na₇PMo₁₁CoO₄₀ strongly inhibit α-glucosidase with IC₅₀ values of 6.14 ± 0.38 μM, 52.33 ± 1.41 μM, 161.90 ± 7.68 μM and 103.10 ± 2.88 μM, respectively. Moreover, H₃PMo₁₂O₄₀, Na₄PMo₁₁VO₄₀, and Na₇PMo₁₁CoO₄₀ are reversible, competitive inhibitors with K_I values of 0.018 mM, 0.146 mM and 0.121 mM, respectively. Na₆PMo₁₁FeO₄₀ inhibited α-glucosidase in a reversible noncompetitive manner with K_I and K_IS of 0.312 mM and 0.412 mM, respectively. Molecular docking simulation suggested that H₃PMo₁₂O₄₀ binds into the substrate binding site in accordance with competitive inhibition behavior and offered, in addition, an initial insight into the polypeptide-inhibitor interactions. This work presents a promising new perspective for designing effective α-glucosidase inhibitors and further demonstrates the enormous potential of polyoxomolybdates as enzyme inhibitors.

Interactions between polyoxometalates and biological systems: from drug design to artificial enzymes

Polyoxometalates have long been studied in a variety of biological applications. Interactions between the highly charged POM molecules and biological molecules frequently occur through hydrogen-bonding and electrostatic interactions. Tellurium-centred Anderson-Evans POMs show exceptional promise as crystallization agents, while acidic and metal-substituted POMs may provide interesting alternatives to enzymes in proteomics applications. While POMs also show interesting results in a number of medicinal applications, for example as anti-amyloid agents for the treatment of Alzheimer's disease and as anti-tumoral agents, their use is often impeded by their toxicity. Many recent studies have therefore focussed on POM-functionalization to reduce toxicity and increase activity by addition of biological targeting molecules.

Selective Targeting of Proteins by Hybrid Polyoxometalates: Interaction Between a Bis-Biotinylated Hybrid Conjugate and Avidin

The Keggin-type polyoxometalate [γ-SiW₁₀O₃₆]^8- was covalently modified to obtain a bis-biotinylated conjugate able to bind avidin. Spectroscopic studies such as UV-vis, fluorimetry, circular dichroism, coupled to surface plasmon resonance technique were used to highlight the unique interplay of supramolecular interactions between the homotetrameric protein and the bis-functionalized polyanion. In particular, the dual recognition mechanism of the avidin encompasses (i) a complementary electrostatic association between the anionic surface of the polyoxotungstate and each positively charged avidin subunit and (ii) specific host-guest interactions between each biotinylated arm and a corresponding pocket on the tetramer subunits. The assembly exhibits peroxidase-like reactivity and it was used in aqueous solution for L-methionine methyl ester oxidation by H₂O₂. The recognition phenomenon was then exploited for the preparation of layer-by-layer films, whose structural evolution was monitored in situ by ATR-FTIR spectroscopy. Finally, cell tracking studies were performed by exploiting the specific interactions with a labeled streptavidin.

Identification of a Wells-Dawson polyoxometalate-based AP-2γ inhibitor with pro-apoptotic activity

AP-2 gamma (AP-2γ) is a transcription factor that plays pivotal roles in breast cancer biology. To search for small molecule inhibitors of AP-2γ, we performed a high-throughput fluorescence anisotropy screen and identified a polyoxometalate compound with Wells-Dawson structure K₆[P₂Mo₁₈O₆₂] (Dawson-POM) that blocks the DNA-binding activity of AP-2γ. We showed that this blocking activity is due to the direct binding of Dawson-POM to AP-2γ. We also provided evidence to show that Dawson-POM decreases AP-2γ-dependent transcription similar to silencing the gene. Finally, we demonstrated that Dawson-POM contains anti-proliferative and pro-apoptotic effects in breast cancer cells. In summary, we identified the first small molecule inhibitor of AP-2γ and showed Dawson-POM-mediated inhibition of AP-2γ as a potential avenue for cancer therapy.

A survey of the different roles of polyoxometalates in their interaction with amino acids, peptides and proteins

This perspective provides a comprehensive description of the different roles of POMs in their interaction with relevant biological molecules.

Target Delivery of a Novel Antitumor Organoplatinum(IV)-Substituted Polyoxometalate Complex for Safer and More Effective Colorectal Cancer Therapy In Vivo

An inactive organoplatinum(IV)-substituted polyoxometalate is developed as an efficient and nontoxic prodrug with significant potential for treating human colorectal cancers. Further encapsulation of Pt(IV) -PW11 with DSPE-PEG2000 nanoparticles (NPs) enables targeted delivery and controlled release of inactive prodrug. Such Pt(IV) -PW11 -DSPE-PEG2000 NPs are highly efficient in inhibiting cellular growth of HT29 cells and treating human colorectal cancer in mice, superior to classic cisplatin.

Polyoxometalate-Based Organic-Inorganic Hybrids as Antitumor Drugs

Polyoxometalates (POMs) have shown encouraging antitumor activity. However, their cytotoxicity in normal cells and unspecific interactions with biomolecules are two major obstacles that impede the practical applications of POMs in clinical cancer treatment. Derivatization of POMs with more biocompatible organic ligands is expected to cause a synergetic effect and achieve improved bioactivity and biospecificity. Herein, the synthesis of an amphiphilic organic-inorganic hybrid is reported by grafting a long-chain organoalkoxysilane lipid onto a POM. The amphiphilic POM hybrid could spontaneously assemble into the vesicles and exhibits enhanced antitumor activity for human colorectal cancer cell lines (HT29) compared to that of parent POMs. This detailed study reveals that the amphiphilic nature of POM hybrids enables the as-formed vesicles to easily bind to the cell membranes and then be uptaken by the cells, thus leading to a substantial increase in antitumor activity. Such prominent antitumor action is mostly accomplished via cell apoptosis, which ultimately results in cell death. Our finding demonstrates that novel POM hybrids-based drugs with increased bioactivity could be obtained by decorating POMs with selective organic ligands.

Gold-nanoparticle-based multifunctional amyloid-β inhibitor against Alzheimer's disease

Targeting amyloid-β (Aβ)-induced complex neurotoxicity has received considerable attention in the therapeutic and preventive treatment of Alzheimer's disease (AD). The complex pathogenesis of AD suggests that it requires comprehensive treatment, and drugs with multiple functions against AD are more desirable. Herein, AuNPs@POMD-pep (AuNPs: gold nanoparticles, POMD: polyoxometalate with Wells-Dawson structure, pep: peptide) were designed as a novel multifunctional Aβ inhibitor. AuNPs@POMD-pep shows synergistic effects in inhibiting Aβ aggregation, dissociating Aβ fibrils and decreasing Aβ-mediated peroxidase activity and Aβ-induced cytotoxicity. By taking advantage of AuNPs as vehicles that can cross the blood-brain barrier (BBB), AuNPs@POMD-pep can cross the BBB and thus overcome the drawbacks of small-molecule anti-AD drugs. Thus, this work provides new insights into the design and synthesis of inorganic nanoparticles as multifunctional therapeutic agents for treatment of AD.

Mo polyoxometalate nanoclusters capable of inhibiting the aggregation of Aβ-peptide associated with Alzheimer's disease

A neuropathological hallmark of Alzheimer's disease (AD) is aggregation of a forty-residue peptide known as amyloid beta forty (Aβ40). While past work has indicated that blocking Aβ40 aggregation could be an effective strategy for the treatment of AD, developing therapies with this goal has been met with limited success. Polyoxometalates (POMs) have been previously investigated for their anti-viral and anti-tumoral properties and we report here that three representative POM nanoclusters have been synthesized for use against Aβ40 aggregation. Through the use of thioflavin T fluorescence, turbidity, circular dichroism spectroscopy, and transmission electron microscopy (TEM), we found that all three POM complexes can significantly inhibit both natural Aβ40 self-aggregation and metal-ion induced Aβ40 aggregation. We also evaluated the protective effect of POM complexes on Aβ40-induced neurotoxicity in cultured PC12 cells and found that treatment with POM complexes can elevate cell viability, decrease levels of intracellular reactive oxygen species, and stabilize mitochondrial membrane potential. These findings indicate that all three representative POM complexes are capable of inhibiting Aβ40 aggregation and subsequent neurotoxicity. While a complete mechanistic understanding remains to be elucidated, the synthesized POM complexes may work through a synergistic interaction with metal ions and Aβ40. These data indicate that POM complexes have high therapeutic potential for use against one of the primary neuropathological features of AD.

Transition-metal-substituted polyoxometalate derivatives as functional anti-amyloid agents for Alzheimer's disease

Inhibitions of amyloid β (Aβ) aggregation and Aβ-haem peroxidase-like activity have received much attention because these two symptoms can be the primary targets of therapeutic strategies for Alzheimer's disease (AD). Recently, our group found that polyoxometalate (POM) with a Wells-Dawson structure can efficiently inhibit Aβ aggregation. However, the interaction between POMs and Aβ is robust, but still needs to improve Aβ binding affinity. More importantly, it is unclear whether POMs can cross the blood-brain barrier and decrease Aβ-haem peroxidase-like activity. Here we show that our designed series of transition metal-functionalized POM derivatives with a defined histidine-chelated binding site have much better Aβ inhibition and peroxidase-like activity inhibition effects than the parent POM. More intriguingly, we show that these compounds can cross the blood-brain barrier and are metabolized after 48 h. Our work provides insights into the design, synthesis and screening of inorganic metal compounds as multifunctional therapeutic agents against AD.

Unprecedented high-nuclear transition-metal-cluster-substituted heteropolyoxoniobates: synthesis by {V8 } ring insertion into the POM matrix and antitumor activities

Reactions of hexaniobate with vanadate in the presence of Ni(2+) , Zn(2+) , or Cu(2+) have furnished three high-nuclear vanadium cluster-substituted heteropolyoxoniobates (HPNs): {Ni(en)3 }5 H{V(V) Nb8 V(IV) 8 O44 }⋅9 H2 O (1), (H2 en)Na2 [{Zn(en)2 (Hen)}{Zn(en)2 (H2 O)}2 {PNb8 V(IV) 8 O44 }]⋅11 H2 O (2), and Na{Cu(en)2 }3 {[Cu(en)2 ]2 [PNb8 V(IV) 8 O44 ]}⋅11 H2 O (3) (en=1,2-diaminoethane). Their structures have been determined and characterized by single-crystal X-ray diffraction analysis, thermogravimetric analysis (TGA), and elemental analysis. Structural analysis has revealed that compounds 1-3 contain similar {V8 }-substituted [X(V) Nb8 V(IV) 8 O44 ](11-) (X=P, V) clusters, obtained by inserting a {V8 } ring into tetravacant HPN [XNb8 O36 ](27-) . To the best of our knowledge, compounds 1-3 represent the first high-nuclear vanadium cluster-substituted HPNs, and compound 1 is the largest vanadoniobate cluster yet obtained in HPN chemistry. Nickel and zinc cations have been introduced into HPNs for the first time, which might promise a more diverse set of structures in this family. Antitumor studies have indicated that compounds 1 and 2 exhibit high activity against human gastric cancer SGC-7901 cells, SC-1680 cells, and MG-63 cells.

The photophysics of europium and terbium polyoxometalates and their interaction with serum albumin: a time-resolved luminescence study

Polyoxometalates (POMs) are emerging as useful materials for a variety of applications. Many show potential for use in the biological and medical fields. Those incorporating lanthanides, with their narrow emission bands, large Stokes' shift and tuneable emission are of particular interest for the labelling and imaging of biological molecules. Their longer emission timescale (micros to ms) also allows autofluorescence from the biological samples to be removed by time gating the emission decay. This means that the characterisation of their photophysical properties is required to enable their application. In this work we present a time-resolved emission study of two types of POM structure, a simple europium containing decatungstate and a more complex high nuclear polyoxotungstate, containing either europium or terbium. A concentration study, made monitoring the lanthanide emission helped elucidate POM-POM interactions. The use of global analysis hints at the presence of defined POM aggregates. Interaction with serum albumin was ascertained, both by monitoring the lanthanide emission of the POM and the tryptophan emission from the serum albumin. This showed that the more complex structure had a significantly higher affinity for the protein than the simple structure.

Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2

Protein kinase CK2 is a multifunctional kinase of medical importance that is dysregulated in many cancers. In this study, polyoxometalates were identified as original CK2 inhibitors. [P2Mo18O62](6-) has the most potent activity. It inhibits the kinase in the nanomolar range by targeting key structural elements located outside the ATP- and peptide substrate-binding sites. Several polyoxometalate derivatives exhibit strong inhibitory efficiency, with IC50 values < or = 10 nM. Furthermore, these inorganic compounds show a striking specificity for CK2 when tested in a panel of 29 kinases. Therefore, polyoxometalates are effective CK2 inhibitors in terms of both efficiency and selectivity and represent nonclassical kinase inhibitors that interact with CK2 in a unique way. This binding mode may provide an exploitable mechanism for developing potent drugs with desirable properties, such as enhanced selectivity relative to ATP-mimetic inhibitors.

Structural characterization and reactivity of gamma-octamolybdate functionalized by proline

The reaction of molybdate and dl-proline at pH 3.4 results in the formation of a Na(4)[Mo(8)O(26)(proO)(2)] x 22H(2)O complex (pro=proline) in which two proline ligands are attached to molybdenum(VI) ions via monodentate coordination of the carboxylate groups. The structure of the complex was determined by single crystal X-ray diffraction and by combination of (1)H, (13)C and (95)Mo NMR spectroscopy techniques in solution. The structure of the complex is strongly dependent on the pH. At native pH 3.4 the octamolybdate-type structure seems to be present in solution, but the increase of pH to 5.8 resulted in a rearrangement of the structure to a heptamolybdate-type structure. At physiological pH, the polyoxometalate framework was completely dissociated into the monomeric MoO(4)(2-) unit. The reactivity of the Na(4)[Mo(8)O(26)(proO)(2)] x 22H(2)O towards the hydrolysis of ATP was tested at different pH values. While in solution at pH 3.4 the hydrolysis proceeded to yield AMP (adenosine monophosphate) and ADP (adenosine diphosphate) in nearly equal amounts, reaction mixture at pH 5.8 gave ADP as the only product of hydrolysis after 24h of reaction. At neutral pH, the hydrolysis of ATP was slower, but it proceeded to yield 75% of ADP after 48 h of reaction.